Therapeutic advances in RRMM: What is the latest on practical application of BCMA-directed therapies?
Update: 2025-09-10
Description
touchEXPERT FOCUS for touchHAEMATOLOGY and touchONCOLOGY
Listen to a series of short expert interviews on the role of B-cell maturation antigen (BCMA)-directed therapies in relapsed/refractory multiple myeloma (RRMM). The faculty discuss patient selection, treatment tailoring and strategies to manage side effects, providing practical guidance for integrating BCMA-targeting approaches into care.
The experts
- Prof. Jesús San Miguel, Cancer Center Clínica Universidad de Navarra (CCUN), Pamplona, Spain
- Prof. Pieter Sonneveld, Erasmus University Medical Center, Rotterdam, The Netherlands
- Dr Francesca Gay, University of Torino, Italy
This touchPODCAST is for HCPs outside of the USA.
This activity is funded by an independent medical education grant from GSK.
This activity is provided by touchIME.
touchIME is an EBAC® accredited provider.
For further information visit our websites: www.touchHAEMATOLOGY.com and www.touchONCOLOGY.com
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
1.0x
